Introduction
Acute graft-versus-host disease (GVHD) still remains a major obstacle after allogeneic stem cell transplantation (SCT) and has a substantial effect on survival. 1 Most patients who develop severe acute GVHD succumb to it, or to complications of the treatment. As the effector cells of GVHD may remain activated in GVHD through complex mechanisms, most of the emphasis in SCT has been concentrated on GVHD prophylaxis. 2 Injury to the gut during conditioning therapy before SCT plays a pivotal role in the initiation of acute GVHD. 3 Damage to the gastrointestinal (GI) tract increases the translocation of inflammatory stimuli such as endotoxin, which promotes further inflammation and additional GI tract damage. The GI tract is critical to the initiation of the 'cytokine storm', characteristic of acute GVHD. 3 It has previously been shown that poor nutritional status before SCT may prolong hospital stay. 4 In critically ill patients, parenteral nutrition (PN) has been associated with mucosal atrophy and an increased risk of infectious complications. 5 PN may also change the local cytokine production profile, resulting in low levels of interleukin (IL)-4 and IL-10. 6 Hence, oral intake after SCT may influence the development of acute GVHD after SCT. In a study conducted at our unit, home care-treated patients had a significantly better daily oral intake and less PN compared with patients treated in hospital. 7 Interestingly, they also showed a significantly lower incidence of acute GVHD grades II-IV. In this study, we investigated whether there was a correlation between oral intake and acute GVHD in patients treated in hospital.
Materials and methods

Patients and donors
Between January 1995 and April 2004, 555 patients were transplanted at Karolinska University Hospital, Huddinge. Three hundred and twenty-four patients were excluded owing to young age (o18 years, n ¼ 115), non-myeloablative SCT (n ¼ 123), non-malignant disease (n ¼ 54), nutritional data not found (n ¼ 20), and early death (o1 month) (n ¼ 12). This left 228 patients for nutritional analysis. There were 135 male and 93 female patients with a median age of 39 (18-60) years. One hundred and twenty-three patients had acute leukaemia, 79 chronic leukaemia, 12 lymphoma, three multiple myeloma, nine MDS, and two myelofibrosis (Table 1) . One hundred and thirty-three (59%) patients were in first remission or chronic phase of their disease and 95 were in later stages. Most of the patients had a sibling or matched unrelated donor. The donors were 133 male and 94 female subjects with a median age of 38 (13-66) years. Patient and donor characteristics are shown in Table 1 .
Nutrition
In the nutritional analysis of the 228 patients, we retrospectively analysed all patient charts for how many days the patients needed PN, how many days the patients had no oral intake, and for how many days they had an oral intake of less than 500 kcal/day. Patients with no oral intake were divided into three groups for further analysis: 1-4 days, 5-8 days, and 49 days. The reason for this was that 95% confidence interval (CI) was 4.5-8.5 days for patients with no oral intake after SCT.
Conditioning
Most patients received cyclophosphamide (Cy), 60 mg/kg, on days À5 and À4 or À4 and À3 before SCT, combined with 10 Gy total-body irradiation (TBI) on day À1 with the lungs shielded to receive no more than 9 Gy. 8 From 1999, TBI was given fractionated (fTBI) 3 Gy/day for 4 days. 9 As an alternative, 80 patients received a combination of busulphan (Bu) (4 mg/kg/day Â 4) and Cy (60 mg/kg Â 2). 10 Patients with a mismatched or unrelated donor were treated for 2-5 days (last dose on day À1) with antithymocyte globulin (ATG) before transplantation. Three different ATG were used: Thymoglobulin (Genzyme, Cambridge, MA, USA) 2 mg/kg/day, ATG-Fresenius 5 mg/kg/day (Fresenius AG, Bad Homburg, Germany), or OKT 3 (Janssen-Cilag, Zug, Switzerland) 5 mg/day.
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Patients with acute lymphocytic leukaemia (ALL), acute myeloid leukaemia (AML) M4, or M5, or those who had history of central nervous system (CNS) leukaemia were given two 12 mg doses of intrathecal methotrexate (MTX) before SCT.
GVHD prophylaxis
Prophylaxis consisted mainly of a combination of cyclosporine (CsA) and a short course of MTX. 12, 13 Nine patients who were expected to develop liver toxicity received prednisolone instead of MTX. As an alternative, CsA was combined with mycofenolate mofetil (MMF), 15 mg/kg 14 given from day 0 to day 45 after haematopoietic stem cell transplantation (HSCT).
Diagnosis and treatment of GVHD
Acute GVHD was diagnosed on the basis of clinical symptoms and/or biopsies of skin, oral mucosa, liver, and gut. GVHD was graded from 0 (absent) to IV according to previously published criteria. 15 At the first sign of grade I GVHD, prednisolone (2 mg/kg day) was given for at least 1 week. 16 Thereafter, the dose was reduced depending on response. Some patients with persistent or severe GVHD also received methylprednisolone i.v., ATG, or psoralene and ultraviolet light (PUVA). 17 In a few patients with recurrent GVHD, MTX, 5-10 mg/m 2 was given once a week.
Histocompatibility locus antigen (HLA) typing
Most patient and donor pairs were HLA-A, -B, and -DR compatible. Before 1997, class I HLA typing was serological. Since then, polymerase chain reaction (PCR)-single strand polymorphism (SSP) low-resolution typing for class I has been used. For HLA class II, the restriction-fragment length polymorphism (RFLP) method was initially used with the help of cDNA probes. Since July 1992, PCR methods that use sequence-specific primer pairs have been employed. Recently, most patients with an unrelated donor have been retrospectively retyped using PCR-SSP highresolution typing for both HLA class I and II antigens.
Stem-cell source and supportive care
One hundred and sixteen patients received stem cells from peripheral blood (PBSC) and 112 bone marrow (BM). Before aphaeresis, all donors of PBSCs were treated with granulocyte colony stimulating factor (G-CSF) (Rhoˆne-Poulenc Rorer, Lyon, France or Amgen-Roche Inc., Thousand Oaks, CA, USA) (10 g/kg/day for 4-6 days). G-CSF was given to 153 (67%) of the patients from day 10 after HSCT until an absolute neutrophil count (ANC) 40.5 Â 10 9 /l for two consecutive days was reached. Thirtythree patients were treated at home directly after SCT. 7 Supportive care has previously been described. 7, 16 Statistical analysis Analysis was performed 10 December 2004. In the uni-and multivariate analyses, logistic regression analyses were used. Factors with a P-value 0.10 on univariate analysis were introduced into the subsequent backwards elimination multivariate analysis. The incidence of acute GVHD was estimated non-parametrically. Patients were censored at the time of GVHD, death, or last follow-up. GVHD and death within 100 days after SCT without GVHD are competing events. Therefore, their incidence rates were estimated using a non-parametric estimator of cumulative incidence curves. Analyses were performed using the cmprsk package (developed by Gray, June 2001), Splus 6.2 software, and Statistica software.
Results
Nutrition
Parenteral nutrition was given for a median of 10 (0-74) days. Twenty-eight patients did not need any PN. Most patients (144, 63%) were able to eat every day during their initial hospital stay, whereas 84 (37%) patients were not able to eat anything (no oral intake) for a median of 4 days (1-37) (Figure 1 ).
Patients
GVHD grade I developed in 111 patients, grade II in 43 patients, grades III-IV in 23 patients, and 51 patients had no GVHD. Five-year overall survivals were 61, 66, 50, and 17% for patients with no, grade I, grade II, and grades III-IV acute GVHD. Eighty-seven patients (38%) had a bacteraemia with one positive blood culture. In patients with a daily oral intake, bacteraemia was detected in 36% compared to 47% of the patients with more than 4 days without an oral intake (NS).
Parenteral nutrition
Patients with GVHD grades III-IV received more PN (median 20, range 0-67) than patients with GVHD grades 0-II (10, 0-74) (P ¼ 0.01). Furthermore, we found a correlation between number of days with PN and bacteraemia (Po0.001) and VOD (P ¼ 0.03). In patients with no, 1-10 days, 11-20 days, and 420 days of PN nutrition, the incidence of bacteraemia was 18, 34, 42, and 54%, respectively.
Oral intake and GVHD
We found a correlation between the number of days with no oral intake (before the diagnosis of acute GVHD) and the incidence of acute GVHD grades III-IV. In patients who had 1-4 days (n ¼ 48) with no oral intake, the incidence of grades III-IV acute GVHD was 6%, in those with 5-8 days (n ¼ 23) it was 17%, and in those with X9 days (n ¼ 13) it was 39% (Figure 2 ). On multivariate logistic regression analysis (corrected for donor type), we found that more than 9 days with no oral intake (OR 7.66, CI 1.44-40.7, P ¼ 0.016), PBSC (5.87, 1.61-21.4, P ¼ 0.007) and GVHD prophylaxis not with CsA þ MTX (OR 16.9, CI 2.75-104, P ¼ 0.002) were independent factors associated with grades III-IV acute GVHD.
Discussion
The gut plays an important role in the immune system, and its function is influenced by different kinds of feeding. 6 The use of enteral nutrition compared to PN results in an important decrease in the incidence of infectious complications in critically ill patients. 18 Gut-associated lymphoid tissue (GALT) has been recognized as the most important factor for the gut immunological barrier. It can be divided into two separate but interconnected compartments: the affector site (Peyer's patches) and effector site (T and B HSCT patients depending on number of days with no oral intake.
Nutrition after allogeneic SCT J Mattsson et al cells in lamina propria). 19, 20 IgA also plays an important role in gut immune defences primarily by preventing the attachment of bacteria to the mucosal cells of the gut. 21 In rats, IgA-positive cells decreased in a dose-dependent fashion when PN increased, and enteral nutrition decreased resulting in increased intestinal permeability. 20 A minor intake of enteral nutrition prevented mucosal atrophy. 20 Parenteral nutrition may also result in lower levels of IL-4 and IL-10 6 and increased expression of interferon-g (IFNg). 22 IL-4 and IL-10 belong to the Th2 response, which may play an important role in the regulation of GVHD. 23 Interferon-g is a crucial cytokine in the second phase of acute GVHD, the activation of donor T cells. Interferon-g levels are significantly higher in mice with acute GVHD than those without the disease. 24 Interferon-g also upregulates several molecules such as adhesion molecules, chemokines, and HLA molecules, which enhances the recruitment of cells and antigen expression. 25 Interferon-g may also cause direct tissue damage to the GI tract. 26 Damage to the GI tract may increase translocation of inflammatory stimuli such as endotoxin, which promotes further inflammation and additional GI tract damage. 3 The GI tract is, therefore, critical to the extension of the 'cytokine storm' of acute GVHD. 3 It has also been shown in animal experiments that the Peyer's patches in the gut seem to be the pivotal anatomical site for the generation of anti-host cytotoxic T cells, resulting in manifestations of acute GVHD. 27 In a recent paper by Goldberg et al.
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gastrointestinal toxicity from the conditioning therapy was correlated to an increased risk of acute GVHD in humans. Taken together, it is possible that nutrition given after allogeneic SCT may influence permeability, cytokine production, and local environment of the GI tract, which in turn may influence the development of acute GVHD after SCT. There are no data available to compare enteral nutrition with PN after SCT. 29 This is not surprising as such a study would be difficult to perform, particularly for ethical reasons. However, a prospective randomized study was performed by Szeluga et al. 30 at the John Hopkins in 1987. This study showed no significant difference in survival between patients receiving total PN compared with enteral nutrition. In a recent study at our unit, patients treated at home showed improved oral intake and needed significantly less PN compared to patients treated in the hospital.
7 Surprisingly, patients receiving home care had a significantly reduced incidence of moderate to severe acute GVHD. 7 In the present study, oral intake before the diagnosis of acute GVHD correlated with severity of acute GVHD -that is, patients with a daily intake had less severe acute GVHD. The degree of oral intake also proved to be the most significant factor associated with severe acute GVHD on multivariate logistic regression analysis. However, there were no differences in bacteraemia between patients with a daily oral intake as opposed to patients with a poor oral intake after SCT. The major pitfall with the present study is that no data for mucositis were available. Therefore, it is possible that patients with a poor oral intake were also those with most damage to the mucosa. This resulted in poor oral intake and an increased risk of developing severe GVHD. Nevertheless, whichever came first, a poor oral intake after SCT identifies patients at high risk for developing severe acute GVHD. Less surprising was the finding that PN was more common in patients developing severe GVHD, as many patients with GVHD involvement of the gut do not tolerate enteral feeding. This may also explain why PN was associated with an increased incidence of bacteraemia, as severe GVHD is associated with a high incidence of infections. 1 The impact of different kinds of nutrition after SCT needs further evaluation. It is conceivable that oral intake may influence the development of severe acute GVHD after SCT. At our unit, we plan to further investigate the role of nutrition after SCT in a prospective study.
